Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review
Archives of Toxicology · 2025
DOI: 10.1007/s00204-024-03941-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Toxicology, 2025. Verfasst von Zhao-Feng Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Chinese Medicinal Materials, Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicin…. Hauptthemen laut MEDLINE: Ginsenosides, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 141 Literaturangaben. Gefördert von: the grants of National Natural Science Foundation of China, National Key Research and Development Program.
Abstract (Originalsprache)
Hepatitis is a chronic inflammatory liver disease and an important cause of liver fibrosis, which can progress to cirrhosis and even hepatocellular carcinoma if left untreated. However, liver fibrosis is a reversible disease, so finding new intervention targets and molecular markers is the key to preventing and treating liver fibrosis. Ginseng, the roots of Panax ginseng C. A. Meyer, is a precious Traditional Chinese Medicines with high medicinal value and is known as the "king of all herbs", and its active ingredient, ginsenoside Rg3 is a rare saponin and a new class of drug, one of the most thoroughly and extensively studied in a large number of studies. Ginsenoside Rg3 is an active ingredient extracted from ginseng that possesses a variety of biological activities, including anti-inflammatory, antioxidant, and anti-fibrotic effects. Several studies have suggested that ginsenoside Rg3 may help reduce hepatic inflammation and oxidative stress, thereby slowing the progression of liver fibrosis. Ginsenoside Rg3 may have some therapeutic effects on liver fibrosis, and the underlying molecular mechanisms behind these effects are attributed to cellular autophagy, apoptosis, and anti-inflammation, as well as the modulation of antioxidant activity and multiple signaling pathways. The molecular mechanisms behind the inhibitory effect of ginsenoside Rg3 on hepatic fibrosis are reviewed, with a view to providing reference for related studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chinese Medicinal Materials, Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicinal Materials, Jilin Agricultural University, Changchun, 130118, China.
- College of Chinese Medicinal Materials, Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicinal Materials, Jilin Agricultural University, Changchun, 130118, China.…
- Engineering Research Center of the Chinese Ministry of Education for Bioreactor and Pharmaceutical Development, College of Life Sciences, Jilin Agricultural University, Changchun, 130118, China. wangyj559@jlau.edu.cn.
- Engineering Research Center of the Chinese Ministry of Education for Bioreactor and Pharmaceutical Development, College of Life Sciences, Jilin Agricultural University, Changchun, 130118, China. liwei7727@126.com.
ORCID-Profile: Wei Li
Förderung
- the grants of National Natural Science Foundation of China
- National Key Research and Development Program
Zitieren
APA
Tian, Z. F., Hu, R. Y., Wang, Z., Wang, Y. J., & Li, W. (2025). Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review. Archives of Toxicology. https://doi.org/10.1007/s00204-024-03941-w
Vancouver
Tian ZF, Hu RY, Wang Z, Wang YJ, Li W. Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review. Archives of Toxicology. 2025. doi:10.1007/s00204-024-03941-w
BibTeX
@article{Tian2025,
author = {Tian, Zhao-Feng and Hu, Rui-Yi and Wang, Zi and Wang, Ya-Jun and Li, Wei},
title = {Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review},
journal = {Archives of Toxicology},
year = {2025},
doi = {10.1007/s00204-024-03941-w}
}
EUVIMED